• PDF / 169,031 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 116 Downloads / 191 Views

DOWNLOAD

REPORT

---

1 S

Respiratory failure and skin rash secondary to off-label use: 2 case reports In a prospective study of 101 patients treated between July 2008 and October 2014, two patients [ages and sexes not stated] were described, who developed respiratory failure (1 patient) and skin rash (1 patient) during off-label treatment with lenalidomide and monthly rituximab for low-grade advanced-stage follicular lymphoma. The treatment with lenalidomide and rituximab was discontinued in both the patients [routes, dosages, duration of treatments to reaction onsets and outcomes not stated]. Strati P, et al. Predictive factors of response and survival of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood 134 (Suppl. 1): 1533, Nov 2019. 803447381 Available from: URL: http://doi.org/10.1182/blood-2019-129311 [abstract]

0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 18 Jan 2020 No. 1787